SINGAPORE, Aug. 26, 2022 — Pfizer has been ranked first in its Covid-19 response, patient centricity, patient safety and bringing innovative, high-quality products amongst pharma companies in Asia in the ‘Corporate Reputation of Pharma’ survey by patient groups across the APAC region.
Overall, the company is ranked second for its corporate reputation across Asian countries and regions.Pfizer moved up in the survey rankings from 4th place to occupy the top ranking from patient groups ‘working’ with Pfizer, representing a significant increase in rankings in 2021 vs. 2020.
This survey, conducted by UK-based PatientView, measures various aspects of pharma’s performance at corporate reputation from a patient perspective. Patient groups responding to this survey are working across therapeutic areas and uniquely positioned to comment on the pharma industry’s performance during the pandemic.Opinions from 300 patient groups from across Asia (Hong Kong, Taiwan, India, Malaysia, Philippines, Australia, S.Korea, mainland China and others) were collected on the performance of the pharmaceutical industry in 2021.
They have collectively been in communication with nearly 2.7 million Asian patients in 2021. A total of 31 pharmaceutical companies were assessed in the Asia edition of this survey.Asian patient groups familiar with and/or working with Pfizer assessed the company to have significantly improved its scores across all indicators of corporate reputation in 2021.
Pharma’s performance at creating vaccines at speed in response to the Covid-19 pandemic convinced most of the respondents of the industry’s and Pfizer’s effectiveness at both innovation and ability to deliver products that truly benefit patients.
“Patients are our North Star. From the earliest stage of drug development to the final approval and use of our medicines and vaccines, our purpose is breakthroughs that change patients’ lives. We work with, and for, patients, advocates, and caregivers to meet the evolving needs of patients everywhere. Colleagues across Pfizer collaborate with patients and patient advocates to develop breakthrough treatments and innovative approaches to help address patient challenges.
“These partnerships have helped to increase patient engagement in research and development, diversify clinical trials, develop patient-friendly educational materials and patient support programs, and elevate priority policy and social impact issues.
“Patients are the focus of everything we do. Everything we do is intended to help patients everywhere live longer and healthier lives”, says Anil Argilla, President, Emerging Markets Asia, Pfizer Biopharmaceuticals Group, Pfizer Inc.
The results of the pharma corporate reputation survey (Asia) are available at here /PRNewswire/